Adagene gets NMPA IND clearance for ADG138
Adagene received NMPA clearance for the IND of ADG138, a double-masked HER2×CD3 T-cell engager, with a Phase 1 study in advanced solid tumors expected to start in China in Q4 2026.
Adagene received NMPA clearance for the IND of ADG138, a double-masked HER2×CD3 T-cell engager. A Phase 1 study in advanced solid tumors is expected to start in China in Q4 2026.